arrow_back Back to App

Extending Support for Rare Pediatric Disease Drug Development

This act extends a program that encourages pharmaceutical companies to develop treatments for rare diseases affecting children. This means parents and children suffering from these conditions may have greater hope for access to new, effective therapies in the future.
Key points
The program encouraging drug development for rare pediatric diseases will be extended until September 30, 2028.
The authority to issue priority review vouchers for such drugs will be extended until September 30, 2030, potentially speeding up their availability.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_7384
Sponsor: Rep. McCaul, Michael T. [R-TX-10]
Process start date: 2024-02-15
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Creating Hope Reauthorization Act of 2024

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_7384.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2024-02-15.

What are the main provisions?

Key points include:

  • The program encouraging drug development for rare pediatric diseases will be extended until September 30, 2028.
  • The authority to issue priority review vouchers for such drugs will be extended until September 30, 2030, potentially speeding up their availability.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. McCaul, Michael T. [R-TX-10].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health